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Background: Vertical transmission of Group B Streptococcus (GBS) is a prerequisite for early-onset dis-
ease and a consequence of maternal GBS colonization. Disease protection is associated with
maternally-derived anti-GBS antibody. Using a novel antibody-mediated C3b/iC3b deposition flow
cytometry assay which correlates with opsonic killing we developed a model to assess the impact of
maternally-derived functional anti-GBS antibody on infant GBS colonization from birth to day 60–89
of life.
Methods: Rectovaginal swabs and cord blood (birth) and infant nasopharyngeal/rectal swabs (birth, day 6
and day 60–89) were obtained from 750 mother/infant pairs. Antibody-mediated C3b/iC3b deposition
with cord and infant sera was measured by flow cytometry.
Results: We established that as maternally-derived anti-GBS functional antibody increases, infant colo-
nization decreases at birth and up to three months of life, the critical time window for the development
of GBS disease. Further, we observed a serotype (ST)-dependent threshold above which no infant was col-
onized at birth. Functional antibody above the upper 95th confidence interval for the geometric mean
concentration was associated with absence of infant GBS colonization at birth for STII (p < 0.001), STIII
(p = 0.01) and STV (p < 0.001). Increased functional antibody was also associated with clearance of GBS
between birth and day 60–89.
Conclusions: Higher concentrations of maternally-derived antibody-mediated complement deposition
are associated with a decreased risk of GBS colonization in infants up to day 60–89 of life. Our findings
are of relevance to establish thresholds for protection following vaccination of pregnant women with
future GBS vaccines.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Background
Group B Streptococcus (GBS) is a major cause of septicemia and
meningitis in infants, affecting 1–2 in every thousand births [1]. An
effective vaccine given to pregnant women would be the most
powerful tool to prevent this condition globally, as it would pro-vide protection for mothers and infants. However, field trials enrol-
ling thousands of pregnant women and infants would be needed to
assess the efficacy of such a vaccine if invasive disease was the
clinical endpoint required to prove efficacy and enable licensure
[2].
An alternative approach is to facilitate the development and
introduction of new vaccines by identifying biomarkers that corre-
late with protection against disease, as were established for Hae-
mophilus influenzae type B [3] and meningococcal diseases [4].
For GBS, it has been shown that high titers of naturally occurring
serotype-specific maternal antibody to capsular polysaccharide
(CPS) correlates with a reduced risk of neonatal disease [5].
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closely with GBS colonization in pregnant women than antibody
concentration assessed by Luminex-binding assay [6]. Antibody-
mediated bacterial killing has also been shown to protect infants
from GBS disease and may be a more useful marker of longevity
than quantifying antibodies using ELISA [5].
Since there are no validated antibody levels associated with
protection from colonization or GBS disease, we assessed the rela-
tionship between antibody-mediated C3b/iC3b deposition against
GBS serotypes Ia, II, III and V and an infant’s risk of acquisition of
the homologous GBS serotypes.2. Methods
2.1. Study design and participants
We undertook a prospective longitudinal cohort study in two
government health centers offering antenatal care to women in
the Fajara area of coastal Gambia, a low-income country with an
annual birth rate of 43.1/1000 population, neonatal sepsis rate of
4.4/1000 live births [7] and neonatal mortality rate of 28/1000 live
births [8]. The study was approved by the joint Gambian Govern-
ment/Medical Research Council Research Ethics Committee, SCC
1350 V4. Eligibility and recruitment details have been previously
described [9].
2.2. Study measures
Participants were followed up daily at home for 6 days and then
asked to return to clinic when the infant was 60–89 days old for
final follow up and vaccinations. Rectovaginal swabs were taken
from enrolled women presenting in labor and cord blood was
taken after delivery but prior to separation of the placenta.
Nasopharyngeal and rectal swabs were taken from all eligible
infants at four hours. Nasopharyngeal and rectal swabs were also
taken from infants at day 6 of life and again at 60 to 89 days of life
together with an infant serum sample.
2.3. Definitions
An infant was deemed to be colonized if either rectal or
nasopharyngeal swabs were positive for GBS (or both). Coloniza-
tion at or after day 6 was defined as rectal colonization as GBS is
unlikely to remain a true colonizer of the nasopharynx. Persistent
colonization was defined as swab-culture positive for GBS at all
three time points; intermittent colonization was defined as
swab-culture positive for GBS on two occasions at either birth
and day 6 or birth and day 60–89 or day 6 and day 60–89, one time
point is defined as swab culture positive for GBS at either birth or
day 6 or day 60–89. The sites and number of infants colonized have
been reported elsewhere [9].
2.4. Laboratory procedures
All swabs were collected in skim-milk tryptone glucose glycerol
(STGG) transport medium, stored at 4 C and transported to the
Medical Research Council laboratories, The Gambia within 4 hours
of collection. On arrival the samples were vortexed briefly and
immediately frozen at 70 C until processing.
All swab specimens were then inoculated into Todd-Hewitt
broth supplemented with colistin and naladixic acid and were pro-
cessed for isolation of GBS using standard laboratory procedures
[10]. Presumptive positive GBS samples were identified by latex
agglutination (Oxoid). All swabs were subjected to real-time poly-
merase chain reaction (PCR) [11]. All GBS positive isolates werethen serotyped using conventional PCR and gel agarose elec-
trophoresis [12].
2.4.1. Complement deposition assay (CDA) [13]
Antibody-mediated C3b/iC3b deposition onto the surface of
formaldehyde-fixed GBS was measured using a flow cytometric
assay performed in 96-well microtitre plates [14]. Briefly, 35 lL
serotype Ia, II, III or V GBS bacteria at 5  14  107 CFU/mL in block-
ing buffer (1% BSA in PBS) were added to 10 lL IgG-depleted
human plasma as the complement source [15] and 5 lL of each test
serum. Plates were incubated for 7.5 min at 37 C with shaking
(900 rpm), and the bacteria pelleted by centrifugation at 3000g
for 5 min. Supernatant was removed and the bacteria washed once
with 200 lL blocking buffer. Bacteria were resuspended in 200 lL
blocking buffer containing 1:500 sheep anti-human C3c FITC
(Abcam) and incubated for 20 min before washing and analysis
by flow cytometry.
2.4.2. Opsonophagocytosis killing assay (OPkA)
The CDA values were compared to OPkA titres obtained for ser-
otypes Ia, III and V using the HL-60 cell line as described [16], using
strains 515 02/2012 (Ia), COH1 11/2013 (III) and CJBIII 03/2009 (V)
(provided by Prof. Carol Baker, Baylor College of Medicine, Hous-
ton, USA). Briefly, heat-inactivated serum sample (12.5 lL) was
mixed with 25 ml of bacteria revived from frozen stock (thawed
and initially resuspended at 5  105 CFU/mL in HBSS and then
diluted 1/2 in HBSS containing 10% baby rabbit complement to give
6250 CFU per well), of GBS strains, 75 lL HL60 cells at a concentra-
tion of 2.6  107 cells/mL and 12.5 ml IgG-depleted human comple-
ment [15]. Samples were incubated at 37 C for 1 hour with
shaking at 600 rpm in a Thermomixer (Eppendorf, Germany).
Two positive controls and six negative controls were added to each
plate. The following negative controls were used: two wells with
bacteria, complement and phagocytes but without human serum;
two wells with bacteria, positive control serum and complement
but without phagocytes and two wells with bacteria, serum,
phagocytes and heat inactivated complement. Before and after
the one-hour incubation (T0 and T60), each reaction was diluted
in sterile water to 1:20, 1:100 and 1:200. 10 lL of each dilution
was subsequently plated by the tilt method onto blood agar plates
and incubated overnight at 37 C in 5% CO2. The opsonophagocytic
activity was determined as the mean log10 reduction in GBS CFU/
mL after 60 min of incubation at 37 C compared to T0 (LogT0-
LogT60). The lowest serum dilution analyzed was 1:30. Thus for sta-
tistical analysis, samples below the limit of detection were
assigned an arbitrary titer of 15.
For both the CDA and the OPkA, results were calibrated with
standard serotype-specific monovalent vaccinee serum kindly pro-
vided by Prof. Carol Baker (as above). CDA results were expressed
at geometric mean (GM) of the fluorescence intensity minus the
complement-only control (FI-C0).
2.5. Statistical analysis
The sample size was calculated on the basis of the previously
observed 24% colonization rate [17], to provide at least 180 colo-
nized women (95% confidence interval (CI) 150–202 women) and
90 colonized infants (95% CI 72–107 infants). The sample size of
180 colonized women was chosen to ensure at least 10 samples
of the least prevalent serotype based on historical data from The
Gambia (serotype III, 6%) [17], in order to allow longitudinal colo-
nization analyses.
Statistical analyses were completed using STATA version 14
(StataCorp 2014, Texas) and GraphPad Prism version 60 (Graph-
Pad Software Inc, La Jolla, California). The operating characteristics
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paired OPkA titer as <30 (<50% killing) or 30 (50% or greater
killing observed). For each pairwise set of comparisons, the sensi-
tivity, specificity, positive predictive value (PPV), negative predic-
tive value (NPV) and positive and negative likelihood ratios (LR
+ = sensitivity/1-specificity and LR = 1-sensitivity/specificity) of
the CDA were calculated.
Potential differences in antibody-mediated C3b/iC3b deposition
between sera from colonized and non-colonized mothers and
infants were evaluated by one-way analysis of variance (ANOVA)
after log transformation of data. Four groups were compared
(mother colonized/infant non-colonized; mother colonized/infant
colonized; mother non-colonized/infant colonized and neither
mother nor infant colonized). The correlation between bacterial
concentration and anti-GBS serotype-specific antibody was evalu-
ated using Deming linear regression and 95% confidence intervals
(GraphPad Software Inc, La Jolla, California). For all comparisons,
p < 0.05 was considered to be significant.
2.6. Role of the funding source
The funders had no role in study design, data collection, data
analysis, data interpretation, or writing of the report. All authors
had full access to all data and the corresponding authors had final
responsibility for the decision to submit for publication.
3. Results
750 mother/infant pairs were recruited between 1st January
2014 and 31st December 2014 [9]. Briefly, two hundred andFig. 1. Correlation between antibody-mediated complement deposition (FI-C0) and op
Correlation between antibody-mediated complement deposition (FI-C0) performed w
correlation coefficient.fifty-three women were GBS-colonized at delivery (33.7%) and
186 newborns (24.8%) were colonized of whom 146 (78.5%) had
GBS in both the nasopharynx and rectum. 181 newborns (24.1%)
were colonized on day 6–9 and 94 infants (13.6%) at day 60–89.
525 serum samples from cord blood and 273 serum samples from
infants at day 60–89 had detectable antibody-mediated C3b/iC3b
deposition against any GBS serotype.
3.1. Correlation between CDA and OPkA
The Pearson product-moment correlation coefficient (r)
between the CDA and OPkA was 0.84 for STIa, 0.79 for STIII and
0.75 for STV (Fig. 1A–C). The overall sensitivity of the CDA for all
serotypes was 80.7% and overall specificity was 90.0% with a
weighted positive likelihood ratio of 8.07 (2.7–23.8) indicating a
strong likelihood that CDA would predict opsonophagocytic killing.
In addition, as formaldehyde may alter the surface components of
the GBS bacteria, we compared results obtained from
formaldehyde-fixed and live serotype III and V bacteria. The live
and fixed assay correlation was highly significant at 0.96 (Fig. 1D).
3.2. Anti-GBS functional antibody in cord sera and maternal
colonization at delivery
Compared to mothers who were not colonized with any GBS
serotype at delivery, mothers colonized with GBS serotypes Ia, II,
III or V had significantly lower GM antibody-mediated C3b/iC3b
deposition in cord blood against the homologous colonizing GBS
ST (Fig. 2). This remained significant after adjustment for maternal
age, previous abortions, number of stillbirths, maternal anemia,sonophagocytosis killing (OPkA) for serotypes Ia (A), II (B) and V (C). Panel (D) –
ith formaldehyde-fixed and live serotype III GBS. r = Pearson product-moment
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Fig. 2. GM antibody-mediated C3b/iC3b deposition (95% CI) in cord blood onto GBS ST Ia, II, III and V. Dot plot demonstrating GM antibody-mediated C3b/iC3b deposition
against GBS STIa, II, III and V in cord blood (n = 525). GM FI-C0 [95% CI] compared between mothers colonized with homologous serotype (colored shapes), non-colonized
mothers (gray shapes) and mothers colonized with other serotypes (blue squares). ANOVA was calculated to compare groups *p < 0.05, **p < 0.01, ****P < 0.001. STIb not
shown.
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birth and season of delivery (Supplementary Table 1).
3.3. Anti-GBS functional antibody in cord sera and maternal and
newborn colonization dynamics at delivery
Antibody-mediated C3b/iC3b deposition was significantly
lower if mother/newborn pairs were both colonized than if
mother/newborn pairs lacked colonization with the homologous
GBS serotype for Ia, II, III and V (p < 0.001) (Fig. 3). If both mother
and newborn were colonized with the homologous GBS serotype,
the GM antibody-mediated C3b/iC3b deposition was significantly
lower than if mother/newborn pairs were colonized with different
GBS serotypes for II (p = 0.002) and III (p = 0.04) but not for Ia(p = 0.3) or V (p = 1.0). There was no difference between the GM
antibody-mediated C3b/iC3b deposition between mother/newborn
colonized pairs and those pairs where mother was non-colonized
and newborn was colonized with the GBS serotype used for anti-
body assessment (p = 1.0 for all GBS serotypes (Fig. 3). Mother/
newborn non-colonized pairs had significantly higher GM
antibody-mediated C3b/iC3b deposition than pairs where infant
but not the mother was colonized for STIa (p = 0.01) and STII
(p < 0.001), but not for STIII or STV. In a multivariable regression
analysis, higher GM antibody-mediated C3b/iC3b deposition was
associated with increasing birth weight and birth during the dry-
hot and wet seasons (compared to the dry cool season). Lower
GM antibody-mediated C3b/iC3b deposition was associated with
malaria in pregnancy and more than two tetanus immunisations
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Fig. 3. Antibody-mediated C3b/iC3b deposition comparing mother and infant colonization groups. Dot plots representing the mean and 95% confidence intervals of log10 FI-C0
values of antibody-mediated C3b/iC3b deposition onto the surface of whole GBS STs Ia, II, III and V bacteria (n = 525). FI-C0 – fluorescence intensity minus complement
control; MI – neither mother nor infant colonized; M+I+(Ia/II/III/V) – both mother and infant colonized with the homologous GBS ST; M+I – mother colonized with
homologous ST, infant non-colonized with any ST; M+I+O – mother and infant colonized with different GBS ST; MI+ – infant colonized with homologous ST, mother non-
colonized with any ST. MI = neither mother nor infant colonized; M+I+ mother and infant colonized; M+I = mother only colonized; MI+ infant only colonized;
ST = serotype. ANOVA was used to compare groups; *p < 0.05; ***P < 0.01; ****p < 0.001. STIb not shown.
Table 1
Multivariate linear regression model of factors associated with antibody-mediated
C3b/iC3b deposition in cord blood.
Variable Coefficient 95% CI p-value
Maternal factors
Age 0.007 0.004 to 0.019 0.223
Weight (kg) 0.000 0.005 to 0.004 0.83
Parity 0.021 0.056 to 0.015 0.25
Malaria in pregnancy 0.338 0.576 to 0.099 0.006
Two tetanus vaccinations
in pregnancy
0.197 0.330 to 0.064 0.004
Infant factors
Birth weight 0.129 0.013–0.245 0.029
Season of birth – dry hot 0.186 0.058–0.314 0.005
Season of birth – Wet 0.209 0.094 to 0.323 <0.001
Female sex 0.019 0.111 to 0.073 0.678
Coefficient describes the expected change in the log odds for a log10 increase in
antibody GM-FI-C0 . A negative coefficient describes a reduction in log odds and a
positive value describes an increase in the log odds taking into consideration all
other variables in the model.
The bold values indicate values with a significance p < 0.05
2974 K. Le Doare et al. / Vaccine 35 (2017) 2970–2978in that pregnancy, when adjusted for maternal age, maternal
weight, previous abortions/stillbirths, maternal anemia, number
of antenatal visits, birth season and gestation (Table 1).
Non-colonized mother/newborn pairs also had significantly higher
GM antibody-mediated C3b/iC3b deposition onto GBS serotypes Ia
(p = 0.001), II (p = 0.001), III (p < 0.001) but not V (p = 1.0), compared
to colonized mothers who delivered non-colonized newborns.3.4. Correlation between antibody-mediated C3b/iC3b deposition and
infant colonization
We identified a GM antibody-mediated C3b/iC3b deposition
value above which we saw no infant colonization for STII, STIII
and STV. There were insufficient data to assess the relationship
between anti-STIa antibody and absence of colonization (n = 3).
This observed cut-off corresponded to antibody-mediated C3b/
iC3b above the upper 95% CI around the GMC for STII, (log FI-
C0 > 3.75, p < 0.001); STIII (log FI-C0 > 3.69, p = 0.01) and STV
(logFI-C0 > 3.73, p < 0.001). (Fig. 4 and Supplementary Table 2).3.5. Clearance of colonization and antibody-mediated C3b/iC3b
deposition
Infants who were persistently colonized with the same GBS ser-
otype from birth to day 60–89 had significantly lower antibody-
mediated C3b/iC3b deposition values than those infants who
remained non-colonized with GBS STII (p < 0.01) and V (p = 0.01).
No infants were persistently colonized with GBS STIa and only
three infants were persistently colonized with GBS STIII. (Fig. 5).
Infants who were intermittently colonized had significantly lower
antibody-mediated C3b/iC3b deposition values for GBS serotypes
Ia (p = 0.005), II (p < 0.001), III (p < 0.001) and V (p = 0.02) com-
pared to infants who remained non-colonized from birth to day
60–89. Infants colonized on only one occasion had significantly
higher antibody concentrations for GBS ST II (p = 0.002) and V
Fig. 4. Infant GBS colonization, functional antibody threshold observed and associated Deming regression with calculated threshold. Scatter plots of log10GBS CFU/mL from
infant swabs and log10 FI-C0: for GBS STII, III and V. Horizontal line represents threshold above which there was no bacterial colonization observed. STII n = 21 STIII n = 10; STV
n = 62.CFU/mL – colony-forming units per milliliter; FI-C0 fluorescence intensity minus C3b/iC3b only control; ST – serotype. Deming regression of log10 FI-C0 against log10
bacterial concentration for GBS ST II, III and V comparing cord serum with CFU/mL from infant swabs at birth. Log10 bacterial concentration on the x-axis (CFU/mL), log10 FI-C0
on the y-axis.
K. Le Doare et al. / Vaccine 35 (2017) 2970–2978 2975(P = 0.05) but not for the other GBS serotypes (STIa p = 0.4, STIII
p = 0.3) compared to infants colonized on two occasions. There
was no significant difference in antibody-mediated complement
deposition between infants colonized on two occasions and infants
who were persistently colonized (GBS ST V p = 0.5, II p = 0.5)
(Fig. 5).4. Discussion
To our knowledge, we present the most comprehensive data of
functional, maternally-derived anti-GBS antibody and infant GBS
colonization from birth to 90 days of life. In particular, we demon-
strate a significant negative association between antibody in cord
blood and infant colonization at birth and during the first 90 days
of life. The data demonstrate that compared to all other mother/
infant groups, the lowest level of functional antibody is found in
mother/infant pairs where both are colonized. Infants receiving
the lowest concentration of functionally active antibody at birth
are also less likely to clear GBS colonization between birth and
day 60–89. Importantly, our data also delineate a threshold of anti-
body above which no infant is colonized.
We show that mothers with high antibody-mediated C3b/iC3b
deposition are less likely to be colonized with GBS than mothers
with lower values. This differs from the findings of a number of
previous studies, which demonstrated higher anti-capsular IgG
concentrations in pregnant women who were colonized with GBS
than in non-colonized women at that particular timepoint [6]. It
is possible that colonized women have higher anti-capsular anti-
body but lower functional antibody and this may account for the
differences between our observations and those of others. The
majority of published studies have focused on anti-capsular
polysaccharide antibody concentration and have not measured
antibody function. It is important to note that while ELISAs arespecific for anti-polysaccharide antibodies, OPkA and complement
deposition assays target both protein and polysaccharide antigens
on the surface of the bacteria [16,18]. Functional assays have been
shown to better predict the duration of protection following vacci-
nation than ELISAs [19,20].
Only two studies have used anti-GBS opsonophagocytosis kill-
ing (OPkA) in longitudinal cohort studies of pregnant women.
Baker et al. [19] used a radioactive antibody binding assay (RABA)
and OPkA to GBS STIII with cord and maternal sera in 10 colonized
women and found that most mothers had low OPkA titres with lit-
tle variation between 28 weeks gestation and delivery. They also
found that mothers colonized with GBS STIII had higher OPkA titres
against GBS STIII than non-colonized mothers [19]. In contrast, a
longitudinal study of 507 pregnant women by Kwatra et al. [6]
found that women who were never colonized during pregnancy
had higher OPkA titres in early pregnancy than those who had
new acquisition of colonization during the study.
Our data show increased functional activity in non-colonized
compared to colonized mothers and an inverse relationship
between cord functional antibody and infant colonization. This
implies that timing of acquisition of GBS by the mother is likely
to be important for transfer of functional antibody from mother
to child and thus protection from infant colonization. It can be pos-
tulated that if acquisition of GBS occurs during pregnancy and is
not yet associated with an immune response in the mother, then
the infant will be exposed to GBS at birth, receive low concentra-
tions of functional maternal antibody and become colonized. Con-
versely, if a mother has previously been colonized and then cleared
this colonization through the development of specific antibody
then she and her infant will be non-colonized. Such infants will
also be less likely to become colonized over the first 90 days of life
through persistence of the maternally derived anti-GBS antibody.
To date, nearly all published work has focused on the role of
antibody in protecting infants from invasive disease [5,20,21] with
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Fig. 5. Median and standard deviation of antibody-mediated C3b/iC3b deposition in cord blood comparing non-colonized, intermittently and persistently colonized infants.
Box and whisker plot with Tukey correction demonstrating median antibody-mediated C3b/iC3b deposition in non-colonized infants, intermittently colonized infants (one
occasion), infants colonized on two occasions and persistently colonized infants with GBS STIa, II, III and V. FI-C0 = fluorescence intensity minus complement control, n = 525.
ANOVA was calculated to determine differences between the four groups, *p < 0.05, **p < 0.03, ***p < 0.01, ****p < 0.001.
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infant colonization and antibody. However, this link is important
because maternal colonization is a prerequisite for early onset dis-
ease and represents the major risk factor for late onset disease.
Studies of H. influenzae type b [22], S. pneumoniae [23] and N.
meningitides [24] demonstrate that increasing antibody concentra-
tions in serum are associated with reduced risk of colonization
with these bacteria. If the same is true of GBS colonization, then
increasing maternally-derived antibody through vaccination could
interrupt GBS colonization and subsequent disease.
Our study has several limitations. The available data relating to
correlates of protection against GBS disease have recently been
reviewed [25], but there are no standardized immunoassays and
the thresholds required for protection are not defined. We are thus
unable to directly compare our results to other studies using differ-
ent assays. As there is no standardized assay for the measurement
of anticapsular antibody we were unable to measure IgG in these
women. We did not use paired mother and cord sera to assess pla-
cental transfer of antibody. Instead, we used cord sera at delivery
and infant sera at day 60–89 as markers of maternal antibody
given that the concentration of antibody that crosses the placenta
and its persistence in the infant are important for protection from
disease [21,26,27].Additionally, we have made some assumptions regarding infant
colonization at birth. Whilst we cannot be certain that infants
found to be colonized at 4 hours of birth represent true coloniza-
tion rather than contamination from secretions following the
birthing process, the fact that 181/186 infants remained colonized
at day 6–9 indicates that this is likely to represent true coloniza-
tion at this point [9].
Our CDA used a 10% complement concentration determined
during assay optimization [13]. This is similar to assays for GBS
developed by GSK (formerly Novartis, 10%), [16] and the Baker lab-
oratories (14%), [28]. The maximal active complement source used
in published assays is 20% [29]. In our assays, we found that 20%
complement gave a high background florescence. Going forward
it will be important to establish assays that use infant complement
which might have different activity compared to the adult comple-
ment used in our assay.
5. Conclusions
In summary, our data suggests that maternal vaccination
against GBS resulting in high levels of functional anti-GBS antibody
is likely to lead to a reduction of maternal and infant colonization
at birth and up to day 89 of life. Our results also demonstrate that it
K. Le Doare et al. / Vaccine 35 (2017) 2970–2978 2977might be possible to develop an immune correlate of protection
from colonization, which could subsequently be validated during
vaccine trials where colonization is additionally evaluated as an
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